USF-LVHN SELECT
A phase I/II study of LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus, combined with nab-paclitaxel and gemcitabine in advanced pancreatic cancer.
Publication/Presentation Date
6-2022
Volume
40
Issue
16
Published In/Presented At
Disciplines
Medical Education | Medicine and Health Sciences
Department(s)
USF-LVHN SELECT Program, USF-LVHN SELECT Program Students
Document Type
Article
COinS
